Comparison
TB-500 vs. Triptorelin
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Healing
Research other
CAS no.
no data
57773-63-4
Molecular weight
888 g/mol
1311.45 g/mol
Half-life
no data
3 h
Sequence
Ac-LKKTETQpGlu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2Mechanism of action
TB-500
Synthetic fragment of the endogenous protein Thymosin Beta-4. In preclinical models, an influence on cell migration, actin sequestration and neovascularisation has been described. Robust human pharmacokinetic data are not publicly available.
Triptorelin
Triptorelin binds with high affinity to the GnRH receptor in the pituitary. After initial stimulation of LH and FSH secretion (flare phase, about 1-2 weeks), receptor desensitisation follows with consecutive gonadotropin suppression. This results in a reversible chemical castration: in men testosterone, in women oestrogen suppression to the postmenopausal range.
Evidence base
Highest evidence
Animal model
Human RCT
Studies
3
4
of which in humans
0
4
Effects recorded
4
3
Open conflicts
1
0
Documented adverse events
2
3